Background:Mitochondrial disease is a rare disorder. It can cause poor growth, developmental delays,muscle weakness, and other symptoms. The disease is usually inherited. It can be presentat birth or develop later in life. Infection is a major cause of disease and death inpeople with this disease. Researchers want to learn more about these infections and thedeclining health of people who have this disease. To do this, researchers will study theDNA of people who become ill. Their DNA will be compared to the DNA of theirhousehold/family members.Objective:To learn more about how genes affect people with mitochondrial disease.Eligibility:People age 2 months and older with mitochondrial disease and their household/familymembers. .Design:Participants will complete a questionnaire about their health history. Their medicalrecords may be reviewed. They will give a blood sample.If the participant becomes ill, they may have a videoconference with a doctor or nurse atthe NIH to perform a physical exam. They may be contacted after their illness to giveupdates on their health. They may be asked to give extra blood samples or complete extraquestionnaires.Participants genetic data will be put into a database. The data will be labeled with acode and not their name. The data will be shared with other researchers.Participation lasts about 1 year. This may be extended if the participant is very ill.
Study Description:
A prospective longitudinal natural history study of acute illness in participants with
Mitochondrial Disease and household/family members.
Objectives:
Primary Objectives: To identify immune signatures that associate with host responses to
disease that would allow improved patient stratification and identification of potential
therapeutic targets to mitigate the severe symptoms and sequelae of infection in
mitochondrial disease.
Secondary Objectives:
1. To correlate immune signatures with quantifiable measures of clinical presentation
to biomarkers of vulnerability and recovery and understand how these measures evolve
over time.
2. To perform exploratory analyses of omic variants, epigenetic signatures, serologic
immune markers, antibody profiles and other possible techniques to discover other
mechanisms of disease and their relationship with patient-centered outcomes.
Endpoints:
Primary Endpoints:
We will perform whole blood transcriptomic analysis, humoral response profiling and
soluble mediator profiling.
Secondary Endpoints:
1. We will collect patient medical records for data abstraction to stratify severity of
illness based on clinical factors (e.g. intensive care status, ventilatory support,
clinical laboratory data, radiology records),
2. We will collect patient centered outcomes data via questionnaires to understand
functional status, healthcare resource access and other sociodynamic factors as they
affect the mitochondrial disease community.
Exploratory Endpoints:
3. We will collect whole blood specimens for sera and DNA that will support these
activities, which will be developed dynamically during the protocol. This will
include next generation sequencing to identify biomarkers associated with parameters
of infection and recovery.
4. We will collect other biological specimens (e.g. cerebral spinal fluid) where
possible for the exploratory analyses outlined above.
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the
following
criteria:
Group 1a
1. Participants must be two months of age or older.
2. Participants must have a diagnosis of mitochondrial disease based on a determination
by a physician with expertise in genetics and/or neurology. Supportive evidence may
include genetic testing, muscle biopsy, biochemical testing, neuroimaging or enzyme
analysis consistent with mitochondrial disease.
3. At the time of enrollment, participants must have suspected or confirmed acute
infection as defined by
1. New onset of any of the following symptoms within one month of enrollment
without an alternative diagnosis: fever, cough, shortness of breath, fatigue,
sore throat, rhinorrhea, musculoskeletal pain, vomiting, diarrhea, anosmia,
neurologic decline; AND report that testing for infection (e.g. respiratory
viral panel, SARS15 COV-2 testing) is clinically indicated based on evaluation
by a healthcare provider.
OR
2. Laboratory confirmed positive testing for an infectious disease as performed at
a local healthcare setting.
Note: At the time of initial approval of this protocol, testing for COVID-19/SARSCov-2
was not consistently available. In order to avoid bias by limiting recruitment to only
those individuals with access to these healthcare resources, inclusion criteria for
participants with acute illness were intentionally kept broad. Participants in Group 1
who were initially suspected to have COVID-19 but later found to have an alternative
infectious illness were used for comparison studies. In 2023, after the end of the
COVID-19 emergency, inclusion criteria for this study were broadened to focus on all
acute infections in mitochondrial disease in order to characterize relationships between
specific pathogens, immunophenotypes and clinical phenotypes in mitochondrial disease.
Please also note that there is no minimum weight requirement for Group 1. However, there
is a minimum weight requirement for phlebotomy procedures. Group 1 participants who do
not meet minimum weight requirements may enroll for records and questionnaires only.
Group 1b
1. Participants must be two months of age or older.
2. Participants must have a diagnosis of mitochondrial disease based on a determination
by a physician with expertise in genetics and/or neurology. Supportive evidence may
include genetic testing, muscle biopsy, biochemical testing, neuroimaging or enzyme
analysis consistent with mitochondrial disease.
3. At the time of enrollment, participants may not have evidence of any acute
infection.
Note: Some participants may initially enroll in Group 1b and later experience acute
infection, in which case they may be moved from Group 1b to Group 1a.
Group 2
1. Participants must be two months of age or older.
2. Participants must weigh greater than 4 kilograms.
3. Participants must be household or family member of a participant in Group 1 above.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation
in this study:
Groups 1 a&b
1. Participants who are less than two months of age.
2. Participants who do not have mitochondrial disease.
3. Study team may decline to enroll a participant for other reasons based on clinical
judgement.
Group 2
1. Participants who are less than two months of age.
2. Participants who are not household or family members of Group 1.
3. Study team may decline to enroll a participant for other reasons based on clinical
judgement.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Investigator: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Contact: 800-411-1222
prpl@cc.nih.gov
Shannon Kruk, R.N.
(301) 451-9145
shannon.kruk@nih.gov
Eliza M Gordon-Lipkin, M.D.
(301) 204-4028
eliza.gordon-lipkin@nih.gov
Eliza M Gordon-Lipkin, M.D., Principal Investigator
National Human Genome Research Institute (NHGRI)